Medios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidating patient-specific manufacturing at its remaining locations in Germany, the company announced. Production has already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation.
The business of patient-specific formulations is under sustained margin pressure, particularly due to price regulatory adjustments, which the company is now countering with measures to increase efficiency. In Germany, Medios operates a network of six GMP manufacturing facilities for patient-specific therapies. GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management. The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.
Thomas Meier, CEO of Medios AG, said: “With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.”
The consolidation is a strategic move to address the challenges in the patient-specific formulations market, where regulatory price adjustments have squeezed margins. By focusing on higher-performing facilities, Medios aims to enhance efficiency and profitability. The closure also underscores the company's commitment to its Operational Excellence Program, which seeks to streamline operations and reduce costs.
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices, and pharmaceutical companies. Medios AG is Germany's first listed specialty pharmaceutical company. The shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index. For more information, visit www.medios.group.
Important events for the Medios Group in the 2026 financial year include the Half-Year Financial Report on August 12, the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day in Breda on September 28 and 29, and the Quarterly Statement as of September 30 on November 10. The original release can be viewed at www.newmediawire.com.
